Company news
HeartSciences Inc. news in 2023
HeartSciences Inc.'s news releases, calls and decks from 2023, newest first.
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
December 13, 2023
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
December 4, 2023
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
November 19, 2023
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
November 12, 2023
HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
September 25, 2023
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
September 20, 2023
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
September 13, 2023
HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
September 6, 2023
HeartSciences Signs Distribution Agreement with FJ Medical, Denmark
August 30, 2023
HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
August 23, 2023
HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio
August 16, 2023
HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results
July 18, 2023
HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
May 8, 2023
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results
March 15, 2023
HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease
February 5, 2023
HeartSciences Announces Further Internationalization of its Patent Portfolio
February 2, 2023
HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
January 3, 2023